BETA
MIT spinout developing microscale magnetic-resonance technology for bioprocess monitoring and oxidative-stress diagnostics.
LarmorBio is a Massachusetts company developing the BioScan-NMR platform, based on microscale magnetic-resonance technology originating at MIT and the Singapore-MIT Alliance for Research and Technology. Its website dates the spinout’s origins to 2021.
The platform addresses two areas: monitoring cells and biological processes in biomanufacturing, and research into blood-based oxidative-stress measurements for diagnostic applications. Its diagnostic programs include metabolic health, pregnancy complications and treatment-response research.
In 2026, LarmorBio and Velocity Bioworks announced a commercial development and license partnership. An October update reported an initial bioprocessing feasibility milestone. Rodolfo Rohr is founder and CEO; Emory Anderson serves on the board.
BioScan-NMR development targets label-free monitoring of cell cultures and fermentation processes. Velocity Bioworks is a commercial development and reference-site partner. [2][6][5]
Research examines oxidative-stress signals in blood for metabolic health and other clinical applications. These programs are distinct from bioprocess-control instrumentation. [3]
BioScan-NMR spans bioprocessing instrumentation and diagnostic research. The diagnostic applications listed by LarmorBio remain under development; a commercial development license for bioprocessing is not a diagnostic marketing authorization. [3][6][5]
An October 15, 2026 partner update reports an initial feasibility evaluation linking NMR measurements with microbial growth indicators. The release describes an early proof of concept and identifies continuous, closed-system monitoring and additional process attributes as further development objectives. [5]
Latest recorded source review: 2026-10-31.
Scope: selected product families.
No commercially marketed product portfolio has been established in the reviewed material.
Microscale nuclear magnetic resonance platform for label-free analysis of cells and small biological samples. Bioprocessing development aims to measure signals through existing tubing for closed-system monitoring. Separate diagnostic research uses blood magnetic-resonance measurements associated with oxidative stress. [2][3][6][5]
Partner evaluation and platform development · diagnostic uses under developmentVelocity Bioworks reported an initial feasibility evaluation with NMR signals correlated to OD600 microbial-growth measurements. [5]
A commercial development and license agreement established a planned reference deployment at Velocity Bioworks in San Antonio. [6]
LarmorBio announced Anderson’s board appointment; its current website continues to list him as a board member. [4]
LarmorBio’s current website dates its MIT spinout origins to 2021. [1]
Accessed 10/31/2026
Last substantive review: 10/31/2026